[CLAIMS]

[Claim 1]

Use of a pharmaceutical composition comprising 4-({(1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof at a lower dose of 10 mg or less and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating or preventing vasomotor symptoms.

[Claim 2]

The use according to claim 1, wherein the lower dose is within the range of 1 mg to 10 mg.

[Claim 3]

The use according to claim 1 or 2, wherein the lower dose is within the range of 5 mg to 10 mg.

[Claim 4]

The use according to claim 1 or 2, wherein the lower dose is within the range of 1 mg to 5 mg.

[Claim 5]

The use according to any one of claims 1 – 3, wherein the lower dose is 10 mg.

[Claim 6]

The use according to any one of claims 1 – 4, wherein the lower dose is 5 mg.

[Claim 7]

The use according to any one of claims 1, 2 and 4, wherein the lower dose is 1 mg.

[Claim 8]

The use according to any one of claims 1 – 7, wherein the medicament is to be administered to a human subject.

[Claim 9]

The use according to claim 8, wherein the human subject is a menopausal woman, a perimenopausal woman, or a postmenopausal woman.

[Claim 10]

The use according to claim 8, wherein the human subject is a cancer patient.

[Claim 11]

The use according to claim 8, wherein the human subject is undergoing or has undergone treatment for cancer.

[Claim 12]

The use according to claim 11, wherein the treatment for cancer is gonadal ablative therapy or gonadal hormonal suppressive therapies.

[Claim 13]

The use according to claim 8, wherein the human subject has undergone surgery.

[Claim 14]

The use according to claim 13, wherein the surgery is hysterectomy, oophorectomy, or orchiectomy.

[Claim 15]

The use according to any one of claims 1 – 14, wherein the vasomotor symptoms are hot flashes.

[Claim 16]

The use according to any one of claims 1 – 14, wherein the vasomotor symptoms are night sweats.

[Claim 17]

The use according to any one of claims 1 – 16, wherein the medicament is to be administered immediately upon sensing the onset of a vasomotor symptom.

[Claim 18]

The use according to any one of claims 1 – 17, wherein the medicament is to be administered daily.

[Claim 19]

The use according to any one of claims 1 – 17, wherein the medicament is to be administered once daily, or twice daily.

[Claim 20]

The use according to any one of claims 1 – 19, wherein the medicament further comprises an additional active agent.